Biogen Shares Rise After Positive Litifilimab Phase 2 CLE Data Biogen reported a second positive Phase 2 litifilimab result at Week 16; data presented Mar 28, 2026 (source: Business Insider/GlobeNewswire).

Biogen Shares Rise After Positive Litifilimab Phase 2 CLE Data: Biogen reported a second positive Phase 2 litifilimab result at Week 16; data presented Mar 28, 2026 (source: Business Insider/GlobeNewswire). 👈 Read full analysis #Biogen #Litifilimab #Phase2ClinicalTrial #Pharmaceuticals #Healthcare

Alteogen and Biogen Partner for The Development of Subcutaneous Biologics with Hybrozyme™ Technology Alteogen Inc. has partnered with Biogen to license its cutting-edge Hybrozyme™ technology for developing two subcutaneous biologics. This collaboration is set to revolutionize patient care, providing innovative therapies.

Alteogen and Biogen Partner for The Development of Subcutaneous Biologics with Hybrozyme™ Technology #South_Korea #Biogen #Daejeon #Alteogen #Hybrozyme

Unveiling Long-Term Benefits of LEQEMBI® in Alzheimer's Treatment: Real-World Insights New findings on LEQEMBI® reveal impressive long-term treatment persistence among patients, showcasing its effectiveness in Alzheimer's care.

Unveiling Long-Term Benefits of LEQEMBI® in Alzheimer's Treatment: Real-World Insights #USA #Cambridge #Eisai #Biogen #LEQEMBI®

Biogen elevated Maria C. Freire to board chair.

Chair changes rarely move stocks — but in biotech, they shape risk posture, pipeline patience, and M&A appetite.

The signal shows up later in capital allocation.

What’s the first behavioral shift you’d look for?

#Biogen #InvestorLens

Three years after its first launch in the US, there are signs that #Biogen and #Eisai's #Alzheimer's #Leqembi therapy is gathering sales momentum.

pharmaphorum.com/news/leqembi...

New LEQEMBI Shot Lets Alzheimer’s Patients Skip Clinic Visits - AktieGo BIIB performance by TradingView Eisai (TYO: 4523) and Biogen (Nasdaq: BIIB) announced that the FDA has accepted a review for their new subcutaneous (under-the-skin) version of LEQEMBI, called LEQEMBI ...

Eisai and Biogen are developing a new version of their Alzheimer’s drug, LEQEMBI IQLIK, that patients could inject at home. The FDA has accepted it for Priority Review, with a decision expected in May 2026.

aktiego.com/new-leqembi-...

#Alzheimers #Healthcare #Biogen #Eisai #Pharma

Something big is coming.

22.01.2026

Stay tuned to our Informed Sport partner Biogen next Thursday for an exciting announcement!

#WeTestYouTrust #InformedSport #Biogen #ComingSoon

Proximity Health Solutions and Biogen Selected as Finalists for '26 SCOPE Engagement Award Proximity Health Solutions and Biogen have been recognized as finalists for the prestigious SCOPE '26 Participant Engagement Award for their impactful lupus webinar series.

Proximity Health Solutions and Biogen Selected as Finalists for '26 SCOPE Engagement Award #USA #Stamford #Biogen #Better_Together #Lupus_Warrior

NICE recommends wider use of Biogen MS drug via NHS NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with multiple sclerosis.

#neurology #NICE #Biogen #natalizumab #Tysabri #multiplesclerosis #MS #activerelapsingremittingmultiplesclerosis #biosimilar #NICEdraftguidance #Sandoz #PolpharmaBiologics #biosimilarequivalent #Tyruko #activerelapsingremittingMS #rapidlyevolvingsevereMS #biosimilarmedicines
zurl.co/tsiGu

#Biogen is facing #biosimilar competition to its big-selling #multiplesclerosis therapy Tysabri in the US for the first time, as #Sandoz enters the market.

pharmaphorum.com/news/sandoz-...

Meanwhile, #Accenture Labs, biotechnology firm #Biogen and quantum computing company #1QBit are collaborating on research related to #drugdiscovery. Quantum computers can compare molecules that are much larger than the ones classical computers can compute, Accenture said on its website.

Vanqua Bio to Present Pre-Clinical Data on VQ-201, a Next Generation C5aR1 Antagonist for the Treatment of Inflammatory Disorders - Vanqua Bio CHICAGO, Dec. 05, 2024 (GLOBE NEWSWIRE) — Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present at the 8th Annual Complement-Based Drug Development Summit, wh...

www.vanquabio.com/vanqua-bio-t...
Looking for this #C5aR1 data. If you attended, could you please share ?
#VanquaBio #InflaRx $IFRX #Biogen $BIIB

At a gathering of biopharma executives, a moment of wonder — and also of worry Sometimes the biggest moments at a conference happen backstage. At the annual STAT Summit, that kind of moment involved a pharma CEO and a toddler in a tuxedo.

At a gathering of biopharma executives, a moment of wonder — and also of worry Sometimes the biggest moments at a conference happen backstage. At the annual STAT Summit, that kind of moment involved a pharma CEO and a toddler in a tuxedo.

Neuromuscular Disease Therapeutics Market's Surge to $45.62 Billion by 2033 Fueled by Innovative Treatments The Neuromuscular Disease Therapeutics Market is projected to soar to $45.62 billion by 2033, driven by groundbreaking advancements in gene therapies and RNA-based treatments.

Neuromuscular Disease Therapeutics Market's Surge to $45.62 Billion by 2033 Fueled by Innovative Treatments #United_States #Austin #Biogen #Neuromuscular #gene_therapies

Pharmalittle: We're reading about Novo Nordisk layoffs, an Amgen discount program, and more In today's Pharmalittle roundup, we're reading about Novo Nordisk layoffs, an Amgen discount program, and more.

Pharmalot.. Pharmalittle.. Good Morning: We’re reading about Novo Nordisk layoffs, an Amgen discount program & much more news.. statnews.com/pharmalot/20... #pharma #Medicare #obesity #weight #patents #layoffs #medicine #Amgen #Gilead #AstraZeneca #NovoNordisk #Biogen #Roche

Eisai and Biogen Unveil New Approach to Early Alzheimer's Treatment Via LEQEMBI® IQLIK™ Injection Eisai and Biogen have launched LEQEMBI® IQLIK™, a new at-home treatment option for early Alzheimer's that enhances patient support during therapy.

Eisai and Biogen Unveil New Approach to Early Alzheimer's Treatment Via LEQEMBI® IQLIK™ Injection #United_States #Cambridge #Eisai #Biogen #LEQEMBI®

Biogen buys CNS delivery specialist Alcyone Therapeutics Biogen buys Alcyone, bringing a partnered technology for delivery of antisense drugs into the central nervous system in-house.

#Biogen has reached a deal to buy #AlcyoneTherapeutics, a privately held company that has developed a system for delivering antisense oligonucleotides (#ASOs) directly into the #centralnervoussystem.

Irene Aranda Carrillo - Conferencia Biogen Científica
Modera: María Monsalve 

#conferenciapatrocinadores #47congresosebbm  #biogen

#Eisai and #Biogen have won FDA approval for a #subcutaneous injection version of Leqembi that could help accelerate uptake of the #Alzheimers disease therapy.

pharmaphorum.com/news/dose-ho...

FDA Greenlights LEQEMBI IQLIK for Subcutaneous Injection in Alzheimer's Care Eisai and Biogen's recent FDA approval of LEQEMBI IQLIK offers a new maintenance option in the battle against early Alzheimer's disease, advancing patient treatment.

FDA Greenlights LEQEMBI IQLIK for Subcutaneous Injection in Alzheimer's Care #USA #Cambridge #Eisai #Biogen #Leqembi

El estudio DEVOTE fue diseñado para evaluar la dosis más elevada de nusinersen en todo el rango de edad, niveles de severidad de la enfermedad y estatus funcional. 🧬

🔗Lee el artículo completo en el siguiente link: lnkd.in/eS2FHNyc

#TheAkariFoundation #AtrofiaMuscularEspinal #Biogen #nusinersen

Obesity Weekly News – August 19th 2025 Obesity Update: Enobosarm’s Oral Release, AI-Powered Drug Discovery, £85M UK-Lilly Obesity Plan, Wegovy’s Price Cut & More   In this […] The post Obesity Weekly News – August 19th 2025 appeared first on LucidQuest Ventures.

FYI: LucidQuest Views >>> Obesity Weekly News – August 19th 2025 #News #AIinPharma #Biogen #Enobosarm #glp1 Comment below!

Obesity Weekly News – August 19th 2025 Obesity Update: Enobosarm’s Oral Release, AI-Powered Drug Discovery, £85M UK-Lilly Obesity Plan, Wegovy’s Price Cut & More   In this […] The post Obesity Weekly News – August 19th 2025 appeared first on LucidQuest Ventures.

ICYMI: LucidQuest Views >>> Obesity Weekly News – August 19th 2025 #News #AIinPharma #Biogen #Enobosarm #glp1 Comment below!

Obesity Weekly News – August 19th 2025 Obesity Update: Enobosarm’s Oral Release, AI-Powered Drug Discovery, £85M UK-Lilly Obesity Plan, Wegovy’s Price Cut & More   In this […] The post Obesity Weekly News – August 19th 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Obesity Weekly News – August 19th 2025 #News #AIinPharma #Biogen #Enobosarm #glp1 Comment below!

The Unseen Blueprint: How North Carolina’s Research Triangle Park Engineered Decades of Economic Growth and Why It’s Changing Now "An analysis of North Carolina's Research Triangle Park, a deliberately engineered tech hub now evolving with new investments and a mixed-use vision."

From Planned Utopia to a $25 Billion Powerhouse: The Strategic Evolution of North Carolina's Research Triangle Park
#ResearchTrianglePark #RTP #NCTech #EconomicDevelopment #Innovation #Biogen #EPA #FactRage #FactRageNews

tglm.us/2YtzG

Aandelen Biogen stijgen door sterke verkoop van Alzheimermedicijn Leqembi Key takeaways De aandelen van Biogen stegen sterk in de vroege handel na de bekendmaking van de resultaten voor het eerste kwartaal, die de verwachtingen van analisten versloegen. Het bedrijf schreef de positieve resultaten gedeeltelijk toe aan de sterke verkoop van het Alzheimer-geneesmiddel Leqembi. Leqembi De Amerikaanse verkoop van Leqembi bedroeg ongeveer 63 miljoen dollar […]

Aandelen Biogen stijgen door sterke verkoop van Alzheimermedicijn Leqembi #Biogen #Leqembi #Alzheimer #aandelen #gezondheid

Actions Biogen en hausse après les ventes exceptionnelles du médicament contre la maladie d’Alzheimer Leqembi Principaux renseignements L’action de Biogen a connu une forte hausse en début de marché suite à la publication de ses résultats du premier trimestre, qui ont dépassé les attentes des analystes. La société a attribué sa performance positive en partie aux ventes robustes de son médicament contre la maladie d’Alzheimer, Leqembi. Leqembi Les ventes américaines […]

Actions Biogen en hausse après les ventes exceptionnelles du médicament contre la maladie d’Alzheimer Leqembi #Biogen #Leqembi #Alzheimer #santé #marché

Biogen raises annual profit forecast on strong demand for rare disease drugs (Reuters) -Biogen raised its annual profit forecast on Thursday, betting on strong demand for its rare disease drugs such as Skyclarys to offset declining sales of its older multiple sclerosis drugs. Shares of the drugmaker rose nearly 8% in premarket trading. The company has focused on deals, cost-cutting measures and newer drugs to address investor pressure for growth, amid declining sales of its aging multiple sclerosis drugs and slow take-up of its Alzheimer’s treatment Leqembi. Biogen (NASDAQ:BIIB) said it does not expect President Donald Trump’s tariff threats to have a material impact on its annual outlook, even if the exemption for pharmaceuticals were to be removed, as a significant portion of its U.S. revenue comes through domestic manufacturing. The company has been expanding its U.S. presence to mitigate any potential tariff impact with a $2 billion investment in its key North Carolina manufacturing facility last week. On an adjusted basis, Biogen expects 2025 profit between $15.50 and $16.00 per share, compared with its previous forecast of $14.50 to $15.50. U.S. sales of Leqembi, which the company sells with Japan’s Eisai, were $63 million for the second quarter. The Wall Street consensus estimate was at $60.5 million, according to brokerage Jefferies.

Click Subscribe #Biogen #RareDiseases #Pharmaceuticals #StockMarket #Investing

Groundbreaking New Data Reveals Four-Year Benefits of LEQEMBI Therapy for Early Alzheimer's Patients Recent findings show that LEQEMBI therapy offers significant cognitive and functional benefits for early Alzheimer's patients over four years.

Groundbreaking New Data Reveals Four-Year Benefits of LEQEMBI Therapy for Early Alzheimer's Patients #Japan #Tokyo #Eisai #Biogen #Leqembi